Effect of Blood-brain Barrier Disruption on Intact and Fragmented Monoclonal Antibody Localization in Intracerebral Lung Carcinoma Xenografts
Overview
Affiliations
Unlabelled: These studies highlight several factors that affect monoclonal antibody (Mab) localization to a tumor in the brain, including tumor permeability, nonspecific and specific binding, plasma half-life, radiolabeled antibody stability and the blood-brain barrier.
Methods: A pancarcinoma Mab [L6 IgG, F(ab')2 and Fab] and an irrelevant isotype-matched antibody [P1.17 IgG and F(ab')2] were given with and without osmotic blood-brain barrier disruption in a LX-1 human small-cell lung carcinoma intracerebral xenograft model.
Results: Intracerebral tumor size and permeability to antibody increased with the selection of 10, 14 or 17 days postinoculation when antibody was administered. Barrier disruption increased the delivery, particularly at earlier time points, which was dependent on antibody-specific and nonspecific binding and tumor permeability. Dehalogenation and/or antibody binding stability also appeared to affect the percent delivery.
Conclusion: These studies demonstrate important variables that should be considered when clinical trials are designed or Mab delivery and localization in intracerebral tumor models are evaluated.
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors.
Bordeau B, Balthasar J Cancer Biol Med. 2022; 18(3).
PMID: 35979855 PMC: 8330533. DOI: 10.20892/j.issn.2095-3941.2020.0704.
Trastuzumab distribution in an and model of brain metastases of breast cancer.
Terrell-Hall T, Nounou M, El-Amrawy F, Griffith J, Lockman P Oncotarget. 2017; 8(48):83734-83744.
PMID: 29137378 PMC: 5663550. DOI: 10.18632/oncotarget.19634.
Weber T, Osl F, Renner A, Poschinger T, Galban S, Rehemtulla A Cancer Res. 2014; 74(7):1913-23.
PMID: 24509903 PMC: 4269941. DOI: 10.1158/0008-5472.CAN-13-3001.
Jin J, Joo K, Nam Y, Kim D, Lee S, Jo M Exp Ther Med. 2012; 1(6):943-946.
PMID: 22993623 PMC: 3445961. DOI: 10.3892/etm.2010.143.
Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases.
Danciu O, Rayani S, Michals E, Villano J Med Oncol. 2012; 29(4):2619-22.
PMID: 22209841 DOI: 10.1007/s12032-011-0148-x.